And Oncolym has been sitting on the shelf for how many years? Not one licensee interested? This was long before Bavi was the new game in town.
Long-term complete responses after (131)I-tositumomab therapy for relapsed or refractory indolent non-Hodgkin's lymphoma. (Source: Br J Cancer.) Full Citation:Br J Cancer. 2006 Jun 19;94(12):1770-6. Epub 2006 May 9.
Publisher's Abstract
Buchegger F, Antonescu C, Delaloye AB, Helg C, Kovacsovics T, Kosinski M, Mach JP, Ketterer N.
[1] 1Service of Nuclear Medicine, University Hospital of Lausanne, CH-1011 Lausanne, Switzerland [2] 2Service of Nuclear Medicine, University Hospital of Geneva, CH-1211 Geneva 14, Switzerland.
We present the long-term results of 18 chemotherapy relapsed indolent (N=12) or transformed (N=6) NHL patients of a phase II anti-CD20 (131)I-tositumomab (Bexxar((R))) therapy study. The biphasic therapy included two injections of 450 mg unlabelled antibody combined with (131)I-tositumomab once as dosimetric and once as therapeutic activity delivering 75 or 65 cGy whole-body radiation dose to patients with normal or reduced platelet counts, respectively. Two patients were not treated due to disease progression during dosimetry. The overall response rate was 81% in the 16 patients treated, including 50% CR/CRu and 31% PR. Median progression free survival of the 16 patients was 22.5 months. Median overall survival has not been reached after a median observation of 48 months. Median PFS of complete responders (CR/CRu) has not been reached and will be greater than 51 months. Short-term side effects were mainly haematological and transient. Among the relevant long-term side effects, one patient previously treated with CHOP chemotherapy died from secondary myelodysplasia. Four patients developed HAMA. In conclusion, (131)I-tositumomab RIT demonstrated durable responses especially in those patients who achieved a complete response. Six of eight CR/CRu are ongoing after 46-70 months.British Journal of Cancer (2006) 94, 1770-1776. doi:10.1038/sj.bjc.6603166 www.bjcancer.com Published online 9 May 2006.